Restricted cubic spline plot of the association between change in eGFR and urinary concentrations of Dickkopf-3 (DKK) and creatinine during the early treatment phase in participants of the STOP-IgAN trial
Levin A, et al.. Global kidney health 2017 and beyond: A roadmap for closing gaps in care, research, and policy. Lancet 2017; 390:1888–1917.
KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2013; [Suppl 3]:1–150.
Coresh J, et al.. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 2014; 311:2518–2531.
Tangri N, et al.. Multinational assessment of accuracy of equations for predicting risk of kidney failure: A meta-analysis. JAMA 2016; 315:164–174.
Porrini E, et al.. Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. Lancet Diab Endocrinol 2015; 3:382–391.
Federico G, et al.. Tubular Dickkopf-3 promotes the development of renal atrophy and fibrosis. J Clin Invest Insight 2016; 1:e84916.
Zewinger S, et al.. Dickkopf-3 (DKK3) in urine identifies patients with short-term risk of eGFR loss. J Am Soc Nephrol 2018; 29:2722–2733.
Rauen T, et al.. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373:2225–2236.